Blockchain Collaboration With UCB

Introduction:

Pharmaceutical company UCB, headquartered in Brussels, has over 8,500 employees operating in over 40 countries. Collaboration is in its DNA, both for projects involving several strategic partners as well as when interacting with end-customers.

The company sought a new, digital way of working that would help eliminate the inefficiencies and frustrations that come with managing complex interactions and processes.

After evaluating a number of options, UCB selected blockchain technology as the most promising solution for its needs. The company is now collaborating with Microsoft on a proof-of-concept (PoC) project to explore how blockchain could be used to streamline clinical trial agreements (CTAs).

The current process for CTAs is manual, paper-based, and time-consuming. Every CTA must be reviewed and approved by multiple parties, which can delay the start of a trial or cause it to be put on hold. In addition, there is no easy way to track changes or ensure that all parties have the most up-to-date version of the agreement.

The PoC will test whether blockchain can help streamline the CTA process by creating a digital, tamper-proof record of CTAs that can be shared with all relevant parties. This would allow UCB to track and manage CTAs more efficiently, while also providing greater visibility into the status of agreements.

If successful, the PoC could pave the way for UCB to use blockchain for other use cases, such as tracking patient consent forms, managing inventory, or streamlining supply chain management. Ultimately, blockchain could help UCB become more agile and efficient in its operations, freeing up resources that can be reinvested in research and development.”

How patients become strategic allies for innovation?

In the past, pharmaceutical companies have faced criticism for being too focused on profit and not sufficiently patient-centric. This has led to a shift in recent years towards greater collaboration with patients, as they are increasingly seen as strategic allies in the development of new treatments and therapies.

One example of this is UCB’s partnership with the European Federation of Neurological Associations (EFNA). The two organizations are working together on a project called “TackleMND”, which is aimed at accelerating the development of new treatments for motor neuron disease (MND). Patients with MND will be involved in every stage of the project, from design and planning to execution and evaluation.

This level of collaboration between patients and pharmaceutical companies is unprecedented, and it is hoped that it will lead to more efficient and effective drug development. In the future, patients could play an even greater role in the innovation process, as their insights and experiences become increasingly valuable.

Blockchain technology could also help to empower patients and give them a greater role in the drug development process. For example, blockchain could be used to create a decentralized database of patient medical records. This would give patients more control over their data and allow them to share it with researchers and pharmaceutical companies on their own terms.

In addition, blockchain could be used to create a decentralized marketplace for clinical trial data. Patients who agree to participate in clinical trials would be able to sell their data directly to pharmaceutical companies, rather than having it collected by third-party research organizations. This would give patients more control over their data and could provide a financial incentive for them to participate in clinical trials.

Ultimately, blockchain technology has the potential to transform the pharmaceutical industry by empowering patients, streamlining clinical trials, and improving drug development. However, it remains to be seen how quickly and extensively the technology will be adopted by the industry.

How Cyberium blockchain can colloborate with UCB?

UCB is a pharmaceutical company that is looking to use blockchain technology to streamline clinical trials and improve drug development. The company has partnered with the European Federation of Neurological Associations (EFNA) on a project called “TackleMND”, which is aimed at accelerating the development of new treatments for motor neuron disease (MND).

Cyberium blockchain could be used to create a decentralized database of patient medical records. This would give patients more control over their data and allow them to share it with researchers and pharmaceutical companies on their own terms. In addition, blockchain could be used to create a decentralized marketplace for clinical trial data. Patients who agree to participate in clinical trials would be able to sell their data directly to pharmaceutical companies, rather than having it collected by third-party research organizations.

Cyberium blockchain is well positioned to help UCB adopt and utilize blockchain technology in its operations.

Join our newsletter


Leave a Reply

Your email address will not be published.